DK3049059T3 - Intranasal dhe formulering til behandlingen af hovedpine - Google Patents

Intranasal dhe formulering til behandlingen af hovedpine Download PDF

Info

Publication number
DK3049059T3
DK3049059T3 DK14830861.2T DK14830861T DK3049059T3 DK 3049059 T3 DK3049059 T3 DK 3049059T3 DK 14830861 T DK14830861 T DK 14830861T DK 3049059 T3 DK3049059 T3 DK 3049059T3
Authority
DK
Denmark
Prior art keywords
headache
treatment
dhe formulation
intranasal
intranasal dhe
Prior art date
Application number
DK14830861.2T
Other languages
English (en)
Inventor
Shunji Haruta
Nikhilesh N Singh
John Kollins
Salvador Rico
Original Assignee
Satsuma Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Satsuma Pharmaceuticals Inc filed Critical Satsuma Pharmaceuticals Inc
Application granted granted Critical
Publication of DK3049059T3 publication Critical patent/DK3049059T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/48Ergoline derivatives, e.g. lysergic acid, ergotamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK14830861.2T 2013-09-24 2014-09-24 Intranasal dhe formulering til behandlingen af hovedpine DK3049059T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361881947P 2013-09-24 2013-09-24
PCT/IB2014/002706 WO2015044782A2 (en) 2013-09-24 2014-09-24 Intranasal dhe for the treatment of headache

Publications (1)

Publication Number Publication Date
DK3049059T3 true DK3049059T3 (da) 2022-01-31

Family

ID=52424045

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14830861.2T DK3049059T3 (da) 2013-09-24 2014-09-24 Intranasal dhe formulering til behandlingen af hovedpine

Country Status (6)

Country Link
US (5) US20160228433A1 (da)
EP (2) EP3049059B1 (da)
JP (2) JP2016531850A (da)
DK (1) DK3049059T3 (da)
ES (1) ES2904570T3 (da)
WO (1) WO2015044782A2 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100383A2 (en) 2008-02-07 2009-08-13 University Of Washington Circumferential aerosol device
RU2728583C2 (ru) 2011-03-03 2020-07-30 Импел Ньюрофарма Инк. Устройство для назальной доставки лекарственных средств
RU2618084C2 (ru) 2011-05-09 2017-05-02 Импел Ньюрофарма Инк. Наконечники для назальной доставки лекарственных средств
US10537692B2 (en) 2013-04-28 2020-01-21 Impel Neuropharma, Inc. Medical unit dose container
CA2998182A1 (en) 2015-09-10 2017-03-16 Impel Neuropharma, Inc. In-line nasal delivery device
WO2018025089A2 (en) 2016-08-05 2018-02-08 Shin Nippon Biomedical Laboratories, Ltd. Pharmaceutical compositions
US20190000753A1 (en) * 2017-07-02 2019-01-03 Dr. Reddy's Laboratories Ltd. Nasal dosage forms of dihydroergotamine
US11571532B2 (en) 2017-11-21 2023-02-07 Impel Pharmaceuticals Inc. Intranasal device with dip tube
CA3081680A1 (en) 2017-11-21 2019-05-31 Impel Neuropharma, Inc. Intranasal device with inlet interface
EP3735244B1 (en) * 2018-01-05 2022-11-23 Impel Pharmaceuticals Inc. Intranasal delivery of dihydroergotamine by precision olfactory device
CA3087698A1 (en) 2018-01-05 2019-07-11 Impel Neuropharma, Inc. Intranasal delivery of olanzapine by precision olfactory device
KR20210034047A (ko) 2018-07-19 2021-03-29 임펠 뉴로파마 인코포레이티드 파킨슨 병 치료를 위한 레보도파 및 도파 데카르복실라아제 저해제의 기도 전달
CA3122396A1 (en) * 2018-12-11 2020-06-18 Satsuma Pharmaceuticals, Inc. Compositions, devices, and methods for treating or preventing headaches
GB2581431A (en) * 2018-12-11 2020-08-19 Satsuma Pharmaceuticals Inc Compositions, devices, and methods for treating or preventing headaches
KR20210109007A (ko) 2019-01-03 2021-09-03 임펠 뉴로파마 인코포레이티드 비강 약물 전달 장치
BR112021023049A8 (pt) 2019-05-17 2022-10-18 Impel Neuropharma Inc Dispositivo de dispensação nasal de uso único

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169849A (en) * 1982-02-01 1992-12-08 Sandoz Ltd. Nasal pharmaceutical compositions
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
ES2239369T3 (es) * 1993-03-26 2005-09-16 Franciscus Wilhelmus Henricus Maria Merkus Composiciones farmaceuticas para administracion intranasal de dihidroergotamina.
JP3197221B2 (ja) * 1996-02-27 2001-08-13 帝人株式会社 吸収性が改善された粉末状経鼻投与組成物
EP1238661A1 (en) * 1999-10-12 2002-09-11 Kaken Pharmaceutical Co., Ltd. Powdery inhalational preparations and process for producing the same
TW553752B (en) * 2001-06-20 2003-09-21 Inhale Therapeutic Syst Powder aerosolization apparatus and method
JP4721212B2 (ja) * 2001-07-05 2011-07-13 株式会社新日本科学 インスリンの経鼻投与用組成物
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
JP4212019B2 (ja) * 2002-01-09 2009-01-21 Translational Research 株式会社 薬物の経鼻投与用組成物
GB0228826D0 (en) * 2002-12-11 2003-01-15 Okpala Joseph Hair technology in creating particles with improved delivery capabilities
WO2004073729A1 (ja) * 2003-02-21 2004-09-02 Translational Research Ltd. 薬物の経鼻投与用組成物
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
US8673360B2 (en) * 2004-08-10 2014-03-18 Shin Nippon Biomedical Laboratories, Ltd. Compositions that enable rapid-acting and highly absorptive intranasal administration
WO2007019229A1 (en) * 2005-08-05 2007-02-15 3M Innovative Properties Company Compositions exhibiting improved flowability
WO2007066646A1 (ja) * 2005-12-06 2007-06-14 Asahi Kasei Chemicals Corporation 高速直接打錠による錠剤の製造方法
CN101668544B (zh) * 2006-12-26 2013-04-24 株式会社新日本科学 经鼻投用制剂
JP2009076785A (ja) * 2007-09-21 2009-04-09 Panasonic Corp 半導体装置の製造方法
EP2429495A4 (en) * 2009-05-15 2014-01-22 Shin Nippon Biomedical Lab Ltd INTRANASAL PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PHARMACOKINETICS
US20110171141A1 (en) * 2009-06-26 2011-07-14 Kellerman Donald J Administration of dihydroergotamine mesylate particles using a metered dose inhaler
WO2011013003A2 (en) 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
EP2558120A4 (en) * 2010-04-15 2013-08-28 Shin Nippon Biomedical Lab Ltd METHOD AND COMPOSITION FOR INTRANASAL ADMINISTRATION
US20110318277A1 (en) * 2010-06-25 2011-12-29 APT Pharmaceuticals, Inc. University of Maryland, Baltimore Tacrolimus compositions for aerosol administration
RU2594244C2 (ru) 2011-01-31 2016-08-10 Син Ниппон Байомедикал Лэборэтэриз, Лтд. Устройства для интраназальной доставки
WO2013090278A2 (en) * 2011-12-11 2013-06-20 Recro Pharma, Inc. Intranasal dexmedetomidine compositions and methods of use thereof

Also Published As

Publication number Publication date
EP3049059B1 (en) 2021-11-03
US20200179379A1 (en) 2020-06-11
ES2904570T3 (es) 2022-04-05
JP6902583B2 (ja) 2021-07-14
WO2015044782A3 (en) 2015-06-11
EP3049059A2 (en) 2016-08-03
WO2015044782A2 (en) 2015-04-02
US20190275036A1 (en) 2019-09-12
JP2020007342A (ja) 2020-01-16
EP4008307A1 (en) 2022-06-08
US20160228433A1 (en) 2016-08-11
US20230000860A1 (en) 2023-01-05
US20240108619A1 (en) 2024-04-04
JP2016531850A (ja) 2016-10-13

Similar Documents

Publication Publication Date Title
DK3049059T3 (da) Intranasal dhe formulering til behandlingen af hovedpine
DK3192902T3 (da) Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3080100T3 (da) Hæmmere af lysinspecifik demethylase-1
DK2983787T3 (da) Fremgangsmåde til behandling af posttraumatisk stresssygdom
DK3603794T3 (da) Fremgangsmåde til overflader med gelmønster
DK3096741T3 (da) Fremgangsmåde til fremstillingen af hybridosomer
DK2994238T3 (da) Belægningsanordning til termisk belægning
DK2954051T3 (da) Modificeret kapsid til genoverførsel til behandling af nethinden
AR095266A1 (es) Inhibidores de bromodominios tetraciclicos
DK3174858T3 (da) Fremgangsmåde til fremstilling af pyrazoler
DK3003699T3 (da) Fodtøjsgenstand og fremgangsmåden til dannelse af genstanden
DK2968208T3 (da) Behandling af kataplexi
DK3007695T3 (da) Sammensætninger og fremgangsmåder til behandling af anæmi
DK3010895T3 (da) Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner
BR112017000042A2 (pt) inibidores de desmetilase-1 lisina-específica
DK3013544T3 (da) Fremgangsmåde til betonfremstilling
DK3288944T3 (da) Imidazopyrazinoner som pde1-inhibitorer
DK2992104T3 (da) Fremgangsmåde til ekspression
DK3021839T3 (da) Sammensætninger for behandling af fibrose
DK3393744T3 (da) Fremgangsmåde til at danne en artikel
DK2836460T3 (da) Fremgangsmåde til fremstilling af graphen
DK3022361T4 (da) Rambuk og fremgangsmåde til anvendelse deraf
FR3001759B1 (fr) Rouge aubagee de turbomachine
DK3259232T3 (da) Fremgangsmåde til aerogeler
FR3000700B1 (fr) Revetement anti-foudre